Wall Street Zen upgrades Enanta Pharmaceuticals stock to Hold

Published on 10/08/2026 at 13:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wall Street Zen moved ENTA to Hold on October 3, 2026. Enanta Pharmaceuticals stock costs EUR 11.05 on October 8, 2026 after EUR 11.05, unchanged.

ENTA, US29251M1062, Illustration mit AI erstellt.

Enanta Pharmaceuticals (ISIN US29251M1062) was upgraded from Sell to Hold by Wall Street Zen on October 3, 2026, as MarketBeat reported. The stock was trading at EUR 11.05 at Lang & Schwarz on October 8, 2026 at 1:37 p.m. CEST, unchanged from its EUR 11.05 prior close on October 7, 2026.

Three recent figures shape ENTA

On August 10, 2026, Zacks reported that Enanta posted an adjusted loss of USD 0.67 per share for the fiscal third quarter ended June 2026, versus a consensus loss of USD 0.37. Revenue reached USD 14.36 million, 20.97 percent below the USD 16.76 million consensus estimate.

On September 23, 2026, HC Wainwright reissued a Buy rating and set a USD 20.00 price objective, according to MarketBeat. On October 3, 2026, Wall Street Zen changed its rating from Sell to Hold, while the reported consensus target stood at USD 19.00.

What does the earnings miss mean?

The fiscal third-quarter revenue gap gives the rating change a clear counterweight. Revenue of USD 14.36 million was USD 2.40 million below consensus, while the adjusted loss exceeded the expected loss by USD 0.30 per share.

Enanta remains a clinical-stage biotechnology company developing small-molecule treatments for viral infections and immunological diseases, including respiratory syncytial virus programs, according to its investor-relations page. The business therefore combines a current royalty-driven revenue base with development spending tied to clinical milestones.

Next reporting date

The next earnings date is November 16, 2026, according to Quartr. That report will provide the next quantified test of revenue, cash use and pipeline progress.

EUR 11.05 holds against prior close

Enanta was trading at EUR 11.05 at Lang & Schwarz on October 8, 2026 at 1:37 p.m. CEST, unchanged versus the EUR 11.05 prior close dated October 7, 2026. The primary Nasdaq context was USD 12.37 at October 7, 2026 at 4:00 p.m. ET, while the 52-week range was USD 10.20 to USD 17.15 and market capitalization was USD 359.7 million as of October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Enanta Pharmaceuticals stock.